Circulating thrombospondin-2 in patients with moderate-to-severe chronic heart failure due to coronary artery disease

Chronic heart failure (CHF) remains a leading cause of morbidity and mortality. In the current study, we aimed to evaluate the predictive value of circulating thrombospondin-2 (TSP-2) for cumulative survival in patients with ischemic CHF due to coronary artery disease (CAD). The results showed that during a median follow-up of 2.18 years, 21 participants died and 106 subjects were hospitalized repeatedly. The median circulating levels of TSP-2 in patients who survived and those who died were 0.63 ng/mL (95%CI50.55-0.64 ng/mL) and 1.03 ng/mL (95% CI50.97-1.07 ng/mL) (P,0.001). Circulating TSP-2 independently predicted all-cause mortality (OR51.27; 95%CI51.08-1.59; P50.002), CHF-related death (OR51.16; 95%CI51.02-1.50; P,0.001), and also CHF-related rehospitalization (OR51.12; 95%CI51.07-1.25; P,0.001). In conclusion, among CAD patients with symptomatic CHF, increased circulating TSP-2 is correlated with increased 3-year CHF-related death, all-cause mortality, and risk for recurrent hospitalization.